Argenica Therapeutics Limited (ASX:AGN)
0.0700
-0.0300 (-30.00%)
Nov 20, 2026, 2:05 PM AEDT
Argenica Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
All FDA-requested assays for xaranetide are complete, enabling IND submission for a phase II-B trial focused on moderate to severe stroke patients. Interim analysis at 50% enrollment will be a key milestone, with strong financial planning and non-dilutive funding supporting both stroke and TBI programs.